Why Has Tempest Therapeutics (NASDAQ:TPST) Lifted 12.06% in Pre-Market Trade on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Has Tempest Therapeutics (NASDAQ:TPST) Lifted 12.06% in Pre-Market Trade on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Tempest Therapeutics (NASDAQ:TPST) was quoted at USD 0.4050 before the open on Tuesday, November 10, 2026, a 12.06% rise on a calculated prior close of USD 0.3614 from Monday, November 9.
Published market data puts the Market Capitalisation at USD 7.23 million across 20.00 million shares, and the 52-week range runs from USD 0.36 to USD 9.75.
Pre-bell trading is very light, with the quote page showing 5,451 shares against a daily average of 2.55 million, roughly 0.21% of a typical session.
Published coverage identifies no trigger for the rise, and the latest cash balance on the quote page is only USD 779,000, which keeps dilution risk elevated.

Drivers of Tempest Therapeutics' Pre-Market Rise (+12.06%)

The indication of USD 0.4050 for Tuesday, November 10, 2026 equals a USD 0.0436 per share gain, worked out from the 12.06% change and the prior close of USD 0.3614. The quote page rounds that prior close to USD 0.36, the floor of the stock's 52-week range. At USD 0.4050 the shares are 95.8% below the 52-week high of USD 9.75 and 12.5% above the low, both calculated. On 20.00 million shares the indicated value is about USD 8.1 million, calculated, against USD 7.23 million on the quote page. Two searches surfaced no corporate announcement, filing or published article dated November 9 or 10, 2026 accounting for the move, so no catalyst can be pinned down.

The Reasoning: No Catalyst Pinned Down, and Common Drivers of Moves Like This

Without news, the move may be mechanical. Generally, a share trading far below USD 1.00 can rebound when short sellers close positions, when a handful of retail buyers hit a thin order book, or when a peer in oncology rallies and lifts related names. Nasdaq's standard rule sets the floor bid at USD 1.00. Shares that finish under that level for 30 straight Business days get a deficiency notice, then a 180-day window to cure, and a reverse split frequently comes next. Firms of this scale often fund via registered direct offerings, which issue fresh shares and can erase a bounce. The latest periodic report is a 10-Q covering the quarter ended June 30, 2026, and a published digest of that span pointed to a cash crunch alongside trial advances.

Valuation, Trading Depth, 52-Week Range and Risks

The USD 7.23 million market capitalisation is small next to the USD 779,000 of cash and short-term investments on the quote page, so that Balance Sheet figure may be out of date and should be checked against the latest 10-Q. Pre-market activity is thin, with 5,451 shares equal to only a few thousand US dollars of turnover, so a handful of orders can shift the indication by several points. The stock sits at the bottom of its 52-week range at USD 0.36, which means a 12.06% bounce still leaves it close to the floor. The main hazards are share issuance and dilution, a Nasdaq bid-price deficiency, discounted financing terms and a Reversal at the opening.

Where Things Stand

Tempest Therapeutics (NASDAQ:TPST) is indicated 12.06% higher pre-market on an unidentified trigger, with no company news found for November 9 or 10, 2026. The shares trade at USD 0.4050, still 95.8% below the USD 9.75 high, with a market capitalisation of USD 7.23 million across 20.00 million shares. Volume of 5,451 shares against a daily average of 2.55 million makes the indication fragile. Watch the 9:30 a.m. ET open, the next filing and any financing announcement.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.